Bioventix PLC
LSE:BVXP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bioventix PLC
Cash & Cash Equivalents
Bioventix PLC
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bioventix PLC
LSE:BVXP
|
Cash & Cash Equivalents
£5.3m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash & Cash Equivalents
£467.7m
|
CAGR 3-Years
12%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Cash & Cash Equivalents
$149.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Cash & Cash Equivalents
£43.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
5%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Cash & Cash Equivalents
£96.9m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
26%
|
|
|
Niox Group PLC
LSE:NIOX
|
Cash & Cash Equivalents
£19.9m
|
CAGR 3-Years
1%
|
CAGR 5-Years
22%
|
CAGR 10-Years
-19%
|
|
Bioventix PLC
Glance View
Bioventix Plc engages in the development and supply of antibodies. The company is headquartered in Farnham, Surrey and currently employs 17 full-time employees. The company went IPO on 2014-04-29. The principal activity of the Company is the development and supply of antibodies. The firm specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics, such as in automated immunoassays used in blood testing. The firm offers a portfolio of antibodies to customers for both commercial use and research and development (R&D) purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The firm also supplies antibody products and services to multinational clinical diagnostics companies. The firm sells its products through direct sales and through distributors.
See Also
What is Bioventix PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
5.3m
GBP
Based on the financial report for Dec 31, 2025, Bioventix PLC's Cash & Cash Equivalents amounts to 5.3m GBP.
What is Bioventix PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
1%
Over the last year, the Cash & Cash Equivalents growth was 3%. The average annual Cash & Cash Equivalents growth rates for Bioventix PLC have been 1% over the past three years , -2% over the past five years , and 1% over the past ten years .
